13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001778253
Total reported value
$928.2M
$928.2M
139 檔
28.5%
The Q3 2025 SEC filing reveals that Ikarian Capital, LLC held a total portfolio value of $928.2M, covering 139 public equity positions.
Ikarian Capital, LLC executed strategic sector rebalancing during Q3 2025, establishing 66 new positions while fully exiting 67 holdings and trimming 33 positions.
In terms of portfolio concentration, the top 5 core holdings (including UTHR, XBI, BMY) accounted for 28.5% of total reported equity market value during Q3 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | UTHR | United Therapeutics CORP | Stock-Healthcare | 9.43% | — | — | |
| 2 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 7.97% | -3.19% | — | |
| 3 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 3.83% | -2.20% | — | |
| 4 | ABVX | Abivax Sa-adr | Stock-Other | 3.54% | +10.00% | — | |
| 5 | ✓ | Uniqure NV | Stock-Other | 3.32% | -0.22% | -33.05% | |
| 6 | INSM | Insmed Inc | Stock-Healthcare | 3.27% | -0.06% | EXIT | |
| 7 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 3.21% | — | — | |
| 8 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 2.97% | +4.52% | — | |
| 9 | CDTX | Cidara Therapeutics Inc | Stock-Other | 2.82% | — | -78.42% | |
| 10 | SRRK | Scholar Rock Holding CORP | Stock-Other | 2.60% | — | +340.95% | |
| 11 | RAPT | Rapt Therapeutics Inc | Stock-Other | 2.16% | — | — | |
| 12 | MAZE | Maze Therapeutics Inc | Stock-Other | 2.04% | +0.27% | +181.96% | |
| 13 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 2.02% | -0.94% | EXIT | |
| 14 | CYTK | Cytokinetics Inc | Stock-Healthcare | 1.94% | -6.65% | EXIT | |
| 15 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 1.94% | — | +979.87% | |
| 16 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 1.72% | — | -10.34% | |
| 17 | HROW | Harrow Inc | Stock-Other | 1.48% | -0.93% | — | |
| 18 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 1.44% | — | — | |
| 19 | ✓ | Biohaven LTD | Stock-Other | 1.27% | — | +165.47% | |
| 20 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 1.26% | -0.24% | +33.94% | |
| 21 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.25% | — | -6.03% | |
| 22 | PCVX | Vaxcyte Inc | Stock-Other | 1.22% | +0.41% | +2.17% | |
| 23 | ANAB | Anaptysbio Inc | Stock-Other | 1.20% | — | +2266.30% | |
| 24 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 1.18% | — | — | |
| 25 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 1.14% | — | — | |
| 26 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 1.14% | — | +418.35% | |
| 27 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 1.09% | -0.19% | EXIT | |
| 28 | CGON | Cg Oncology Inc | Stock-Other | 1.07% | — | +60.95% | |
| 29 | TVTX | Travere Therapeutics Inc | Stock-Other | 1.03% | — | — | |
| 30 | ✓ | Jazz Pharmaceuticals PLC | Stock-Other | 0.99% | — | — | |
| 31 | ✓ | Zura Bio LTD | Stock-Other | 0.98% | +0.19% | — | |
| 32 | ✓ | Stock-Other | 0.95% | — | +122.46% | ||
| 33 | NVO | Novo-nordisk A/s-spons Adr | Stock-Healthcare | 0.88% | -1.19% | EXIT | |
| 34 | MBX | Mbx Biosciences Inc | Stock-Other | 0.83% | — | — | |
| 35 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 0.79% | -0.06% | EXIT | |
| 36 | TENX | Tenax Therapeutics Inc | Stock-Other | 0.78% | +0.38% | — | |
| 37 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.72% | +1.51% | -75.24% | |
| 38 | KOD | Kodiak Sciences Inc | Stock-Other | 0.72% | +1.13% | -30.97% | |
| 39 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 0.67% | — | -16.66% | |
| 40 | ACOG | Alpha Cognition Inc | Stock-Other | 0.65% | +0.18% | +3.09% | |
| 41 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 0.60% | — | — | |
| 42 | GMAB | Genmab A/s -sp Adr | Stock-Other | 0.56% | — | — | |
| 43 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.56% | +0.84% | NEW | |
| 44 | PHVS | Pharvaris N.V. | Stock-Other | 0.56% | +0.03% | — | |
| 45 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.54% | — | — | |
| 46 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 0.52% | -0.06% | EXIT | |
| 47 | DCTH | Delcath Systems Inc | Stock-Other | 0.49% | -0.07% | +33.77% | |
| 48 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.48% | — | -10.84% | |
| 49 | LQDA | Liquidia CORP | Stock-Other | 0.48% | — | — | |
| 50 | FBRX | Forte Biosciences Inc | Stock-Other | 0.48% | -0.20% | -37.03% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | INSM | Insmed Inc | +2.3% | +30.53% | Add |
| 2 | CDTX | Cidara Therapeutics Inc | +2% | -78.42% | Add |
| 3 | APLSUSD | Apellis Pharmaceuticals Inc | +1.7% | +979.87% | Add |
| 4 | MAZE | Maze Therapeutics Inc | +1.5% | +181.96% | Add |
| 5 | HROW | Harrow Inc | +1.2% | — | Add |
| 6 | FULC | Fulcrum Therapeutics Inc | +1.1% | +33.94% | Add |
| 7 | SRRK | Scholar Rock Holding CORP | +1.1% | +340.95% | Add |
| 8 | CYTK | Cytokinetics Inc | +1.1% | -13.01% | Add |
| 9 | KOD | Kodiak Sciences Inc | +0.5% | -30.97% | Trim |
| 10 | ✓ | +0.4% | +122.46% | Add | |
| 11 | RLMD | Relmada Therapeutics Inc | +0.4% | +4476.76% | Add |
| 12 | DCTH | Delcath Systems Inc | +0.3% | +33.77% | Add |
| 13 | SLDB | Solid Biosciences Inc | +0.3% | — | Add |
| 14 | VTYXUSD | Ventyx Biosciences Inc | +0.2% | +35.35% | Add |
| 15 | PCVX | Vaxcyte Inc | +0.2% | +2.17% | Add |
| 16 | ALT | Altimmune Inc | +0.2% | +20.85% | Add |
| 17 | PEPG | Pepgen Inc | +0.2% | +257.31% | Add |
| 18 | MLTX | Moonlake Immunotherapeutics | +0.2% | +418.35% | Add |
| 19 | LRMR | Larimar Therapeutics Inc | +0.2% | — | Add |
| 20 | LXEO | Lexeo Therapeutics Inc | +0.1% | +3.19% | Add |
| 21 | ALEC | Alector Inc | +0.1% | -15.56% | Trim |
| 22 | TEVA | Teva Pharmaceutical-sp Adr | 0% | — | Unchanged |
| 23 | VTGN | Vistagen Therapeutics Inc | 0% | +3.19% | Add |
| 24 | ARCT | Arcturus Therapeutics Holdin | 0% | +35.95% | Trim |
| 25 | 430 | Terns Pharmaceuticals Inc | 0% | +180.73% | Trim |
| 26 | BRD1EUR | Mind Medicine Mindmed Inc | 0% | — | Unchanged |
| 27 | PRAX | Praxis Precision Medicines I | 0% | -75.24% | Trim |
| 28 | RLAY | Relay Therapeutics Inc | 0% | -37.12% | Trim |
| 29 | ANEB | Anebulo Pharmaceuticals Inc | 0% | — | Unchanged |
| 30 | ABOS | Acumen Pharmaceuticals Inc | 0% | — | Unchanged |
| 31 | EVAX | Evaxion A/s | 0% | — | Unchanged |
| 32 | KPTI | Karyopharm Therapeutics Inc | 0% | — | Unchanged |
| 33 | VYGR | Voyager Therapeutics Inc | 0% | — | Unchanged |
| 34 | AVTX | Avalo Therapeutics Inc | — | +352.63% | Trim |
| 35 | JSPR | Jasper Therapeutics Inc | — | — | Unchanged |
| 36 | ACOG | Alpha Cognition Inc | 0% | +3.09% | Trim |
| 37 | ARVN | Arvinas Inc | 0% | -73.38% | Trim |
| 38 | ANRO | Alto Neuroscience Inc | 0% | — | Trim |
| 39 | 2KZ0 | Kezar Life Sciences Inc | 0% | — | Unchanged |
| 40 | TOVX | Theriva Biologics Inc | 0% | — | Unchanged |
| 41 | RNAC | Cartesian Therapeutics Inc | 0% | — | Unchanged |
| 42 | AKRO | Akero Therapeutics Inc | 0% | -6.03% | Add |
| 43 | ✓ | 0% | -55.99% | Trim | |
| 44 | QURE | uniQure N.V. | 0% | -51.15% | Trim |
| 45 | LXRX | Lexicon Pharmaceuticals Inc | -0.1% | — | Trim |
| 46 | SGMOQ | Sangamo Therapeutics Inc | -0.1% | +2.74% | Trim |
| 47 | VTLUSD | Immunic Inc | -0.1% | — | Trim |
| 48 | CAPR | Capricor Therapeutics Inc | -0.1% | -77.45% | Add |
| 49 | FBRX | Forte Biosciences Inc | -0.1% | -37.03% | Trim |
| 50 | DRUG | Bright Minds Biosciences Inc | -0.2% | -76.42% | Trim |
According to official SEC Form 13F filings, Ikarian Capital, LLC reported a total U.S. public equity portfolio value of $928.2M across 139 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
UTHR
市值: $88.9M
Top Position Liquidated / Trimmed
SPY
前期市值: $193.0M
During Q3 2025, Ikarian Capital, LLC's top holdings by market value included UTHR (9.4%)、XBI (8.0%)、BMY (3.8%). The largest single position, UTHR, represented 9.4% of total portfolio value.
In Q3 2025, Ikarian Capital, LLC made 189 total portfolio adjustments, initiating 66 new buys, adding to 23 positions, trimming 33 holdings, and fully liquidating 67 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.